Effect of the use of prediagnosis hormones on breast cancer prognosis: MCC-Spain study.
Journal
Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
19
10
2022
medline:
1
11
2022
entrez:
18
10
2022
Statut:
ppublish
Résumé
To extend knowledge about the long-term use of hormones in hormone therapy or oral contraception as prognostic factors in breast cancer. The MCC-Spain project is a cohort of 1,685 women with incident breast cancer recruited in Spain. Recruitment was carried out between 2007 and 2010, and the follow-up finished in December 2017. The impact of hormone therapy or oral contraception on breast cancer prognosis was analyzed considering year of birth and menopausal status (1,095 women [65%] were postmenopausal). Hazard ratios (HRs) were estimated using Cox regression models. Death by any cause was considered as the event, and hormone therapy or oral contraception were analyzed as regressors. Oral contraception use for less than 5 years shows an HR of 1.10 (95% CI, 0.75 to 1.62), whereas use for 5 or more years shows an HR of 1.46 (95% CI, 0.95 to 2.25), with a P trend of 0.01, showing a dose-dependent response. Regarding hormone therapy and restricting the analysis to postmenopausal women born between1940 and 1959, where most hormone therapy (consumption) is concentrated, the results did not show any trend. Concerning oral contraception use, our results demonstrate that their use is related to poor prognosis in breast cancer. However, research in this field is limited and controversial, indicating the need for more research in this area. Regarding hormone therapy consumption, our results indicate no association with better prognosis, which contradicts what has previously been published.
Identifiants
pubmed: 36256924
doi: 10.1097/GME.0000000000002069
pii: 00042192-202211000-00013
doi:
Substances chimiques
Hormones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1315-1322Informations de copyright
Copyright © 2022 by The North American Menopause Society.
Déclaration de conflit d'intérêts
Financial disclosure/conflicts of interest: N.A.'s institution has received funding from Instituto de Salud Carlos III and Fundación para la Investigación e Innovación Biosanitaria de Atención Primaria. The other authors have nothing to declare.
Références
International Agency for Research on Cancer. Cancer Today. The global cancer observatory. Published 2018. Available at: https://gco.iarc.fr/today/online-analysis-multi-bars?v=2018&mode=cancer&mode_population=countries&population=900&populations=724&key=cum_risk&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=3&ages_group%5B%5D=14&nb_item . Accessed February 14, 2020.
World Health Organization. Cancer. https://www.who.int/en/news-room/fact-sheets/detail/cancer . Accessed April 18, 2022.
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview [published online April 5, 2021]. Int J Cancer doi: 10.1002/ijc.33588
doi: 10.1002/ijc.33588
Guevara M, Molinuevo A, Salmerón D, et al. Cancer survival in adults in Spain: a population-based study of the Spanish Network of Cancer Registries (REDECAN). Cancers (Basel) 2022;14:2441. doi: 10.3390/cancers14102441
doi: 10.3390/cancers14102441
Al-Ajmi K, Lophatananon A, Yuille M, Ollier W, Muir KR. Review of non-clinical risk models to aid prevention of breast cancer. Cancer Causes Control 2018;29:967–986. doi: 10.1007/s10552-018-1072-6
doi: 10.1007/s10552-018-1072-6
Huzell L, Persson M, Simonsson M, et al. History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response. Breast Cancer Res Treat 2015;149:505–515. doi: 10.1007/s10549-014-3252-8
doi: 10.1007/s10549-014-3252-8
de Almeida Chuffa LG, Lupi-Júnior LA, Balandis Costa A, de Arruda Amorim JP, Rodrigues Ferreira Seiva F. The role of sex hormones and steroid receptors on female reproductive cancers. Steroids 2017;118:93–108. doi: 10.1016/j.steroids.2016.12.011
doi: 10.1016/j.steroids.2016.12.011
Navarro Góttiez H, Morera Montes J. Los anticonceptivos orales: criterios de selección, utilización y manejo. Ministerio de sanidad. https://www.sanidad.gob.es/biblioPublic/publicaciones/recursos_propios/infMedic/porVolumen/anticonc.htm . Accessed March 18, 2022.
Baladé Martínez L, Montero Corominas D, Macías Saint-Gerons D. Utilization of hormone replacement therapy in Spain: trends in the period 2000-2014 [in Spanish]. Med Clin (Barc) 2016;147:287–292. doi: 10.1016/j.medcli.2016.05.023
doi: 10.1016/j.medcli.2016.05.023
NIH (Instituto Nacional del Cancer). Terapia hormonal para la menopausia y el cáncer—Instituto Nacional del Cáncer. Published 2018. https://www.cancer.gov/espanol/cancer/causas-prevencion/riesgo/hormonas/hoja-informativa-hormonas-menopausia . Accessed March 18, 2022.
Mendoza N, Abad P, Baró F, et al. Spanish Menopause Society position statement: use of tibolone in postmenopausal women. Menopause 2013;20:754–760. doi: 10.1097/gme.0b013e31827b18c5
doi: 10.1097/gme.0b013e31827b18c5
United Nations Department of Economic and Social Affairs. Contraceptive Use by Method 2019 . United Nations; 2019. doi: 10.18356/1bd58a10-en
Sociedad Española de contracepción. Presentada la Encuesta Nacional 2018 sobre la Anticoncepción en España. Published 2018. http://sec.es/presentada-la-encuesta-nacional-2018-sobre-la-anticoncepcion-en-espana/ . Accessed April 18, 2022.
Olsson H, Moller TR, Ranstam J, Borg A, Ferno M. Early oral contraceptive use as a prognostic factor in breast cancer. Anticancer Res 1988;8:29–32. doi: 10.1016/0022-4731(87)91258-1
doi: 10.1016/0022-4731(87)91258-1
Schönborn I, Nischan P, Ebeling K. Oral contraceptive use and the prognosis of breast cancer. Breast Cancer Res Treat 1994;30:283–292. doi: 10.1007/BF00665969
doi: 10.1007/BF00665969
Sauerbrei W, Blettner M, Schmoor C, Bojar H, Schumacher M. The effect of oral contraceptive use on the prognosis of node positive breast cancer patients. Eur J Cancer 1998;34:1348–1351. doi: 10.1016/S0959-8049(98)00139–7
doi: 10.1016/S0959-8049(98)00139–7
Trivers KF, Gammon MD, Abrahamson PE, et al. Oral contraceptives and survival in breast cancer patients aged 20 to 54 years. Cancer Epidemiol Biomarkers Prev 2007;16:1822–1827. doi: 10.1158/1055-9965.EPI-07-0053
doi: 10.1158/1055-9965.EPI-07-0053
Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 2010;82:221–229. doi: 10.1016/j.contraception.2010.04.006
doi: 10.1016/j.contraception.2010.04.006
Simonsson M, Björner S, Markkula A, et al. The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size. Int J Cancer 2017;140:163–175. doi: 10.1002/ijc.30432
doi: 10.1002/ijc.30432
Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013;49:52–59. doi: 10.1016/j.ejca.2012.07.003
doi: 10.1016/j.ejca.2012.07.003
Wilson RA, Evans M. Feminine Forever . Simon & Schuster of Canada: Lippincott; 1996.
Cagnacci A, Venier M. The controversial history of hormone replacement therapy. Medicina (B Aires) 2019;55:1–11. doi: 10.3390/medicina55090602
doi: 10.3390/medicina55090602
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333. doi: 10.1001/jama.288.3.321
doi: 10.1001/jama.288.3.321
Hodis HN, Bauer HJ. Menopausal hormone therapy and breast cancer: what is the evidence from randomized trials? Climacteric 2018;21:521–528. doi: 10.1080/13697137.2018.1514008.Menopausal
doi: 10.1080/13697137.2018.1514008.Menopausal
Costas L, Sequera V-GG, Quesada P, et al. Hormonal contraception and postmenopausal hormone therapy in Spain: time trends and patterns of use. Menopause 2015;22:1138–1146. doi: 10.1097/GME.0000000000000487
doi: 10.1097/GME.0000000000000487
Isidoro B, Lope V, Whelan D, et al. Use of hormone therapy and isoflavones and mammographic density in Spain. Menopause 2016;23:556–564. doi: 10.1097/GME.0000000000000569
doi: 10.1097/GME.0000000000000569
Mamluk L, Edwards HB, Savović J, et al. Low alcohol consumption and pregnancy and childhood outcomes: time to change guidelines indicating apparently 'safe' levels of alcohol during pregnancy? A systematic review and meta-analyses. BMJ Open 2017;7:e015410. doi: 10.1136/bmjopen-2016-015410
doi: 10.1136/bmjopen-2016-015410
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394:1159–1168. doi: 10.1016/S0140-6736(19)31709-X
doi: 10.1016/S0140-6736(19)31709-X
Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA 2020;324:369–380. doi: 10.1001/jama.2020.9482
doi: 10.1001/jama.2020.9482
Brinton LA, Brogan DR, Coates RJ, Swanson CA, Potischman N, Stanford JL. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause 2018;25:1195–1200. doi: 10.1097/GME.0000000000001217
doi: 10.1097/GME.0000000000001217
Yu X, Zhou S, Wang J, et al. Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies. Breast Cancer 2017;24:643–657. doi: 10.1007/s12282-017-0789-5
doi: 10.1007/s12282-017-0789-5
Obi N, Heinz J, Seibold P, et al. Relationship between menopausal hormone therapy and mortality after breast cancer the MARIEplus study, a prospective case cohort. Int J Cancer 2016;138:2098–2108. doi: 10.1002/ijc.29951
doi: 10.1002/ijc.29951
Holm M, Olsen A, Kroman N, Tjønneland A. Lifestyle influences on the association between pre-diagnostic hormone replacement therapy and breast cancer prognosis—results from The Danish ‘Diet, Cancer and Health’ prospective cohort. Maturitas 2014;79:442–448. doi: 10.1016/j.maturitas.2014.09.004
doi: 10.1016/j.maturitas.2014.09.004
Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative observational study. J Natl Cancer Inst 2013;105:526–535. doi: 10.1093/jnci/djt043
doi: 10.1093/jnci/djt043
Godina C, Ottander E, Tryggvadottir H, Borgquist S, Isaksson K, Jernström H. Prognostic impact of menopausal hormone therapy in breast cancer differs according to tumor characteristics and treatment. Front Oncol 2020;10(February):1–12. doi: 10.3389/fonc.2020.00080
doi: 10.3389/fonc.2020.00080
Castaño-Vinyals G, Aragonés N, Pérez-Gómez B, et al. Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design. Gac Sanit 2015;29:308–315. doi: 10.1016/j.gaceta.2014.12.003
doi: 10.1016/j.gaceta.2014.12.003
Alonso-Molero J, Molina AJ, Jiménez-Moleón JJ, et al. Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results. BMJ Open 2019;9:1–11. doi: 10.1136/bmjopen-2019-031904
doi: 10.1136/bmjopen-2019-031904
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–1474. doi: 10.1245/s10434-010-0985-4
doi: 10.1245/s10434-010-0985-4
Gómez-Acebo I, Dierssen-Sotos T, Palazuelos-Calderón C, et al. Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study. Breast Cancer Res Treat 2020;181:667–678. doi: 10.1007/s10549-020-05600-x
doi: 10.1007/s10549-020-05600-x
Nur U, El Reda D, Hashim D, Weiderpass E. A prospective investigation of oral contraceptive use and breast cancer mortality: findings from the Swedish Women's Lifestyle and Health cohort. BMC Cancer 2019;19:807. doi: 10.1186/s12885-019-5985-6
doi: 10.1186/s12885-019-5985-6
Ettinger B, Wang SM, Leslie RS, et al. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause 2018;25:1306–1312. doi: 10.1097/GME.0000000000001233
doi: 10.1097/GME.0000000000001233
Abenhaim HA, Suissa S, Azoulay L, Spence AR, Czuzoj-Shulman N, Tulandi T. Menopausal hormone therapy formulation and breast cancer risk. Obstet Gynecol 2022;139:1103–1110. doi: 10.1097/AOG.0000000000004723
doi: 10.1097/AOG.0000000000004723
Samson ME, Adams SA, Mulatya CM, et al. Types of oral contraceptives and breast cancer survival among women enrolled in Medicaid: a competing-risk model. Maturitas 2017;95:42–49. doi: 10.1016/j.maturitas.2016.10.014
doi: 10.1016/j.maturitas.2016.10.014
Morra A, Jung AY, Behrens S, et al. Breast cancer risk factors and survival by tumor subtype: pooled analyses from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2021;30:623–642. doi: 10.1158/1055-9965.EPI-20-0924
doi: 10.1158/1055-9965.EPI-20-0924
Rosenberg LU, Granath F, Dickman PW, et al. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res 2008;10:16–20. doi: 10.1186/bcr2145
doi: 10.1186/bcr2145
Jolleys JV, Olesen F. A comparative study of prescribing of hormone replacement therapy in USA and Europe. Maturitas 1996;23:47–53. doi: 10.1016/0378-5122(95)00952-3
doi: 10.1016/0378-5122(95)00952-3
Crawford SL, Crandall CJ, Derby CA, et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative study results. Menopause 2019;26:588–597. doi: 10.1097/GME.0000000000001282
doi: 10.1097/GME.0000000000001282
Ereman RR, Prebil LA, Mockus M, et al. Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California. BMC Public Health 2010;10:228. doi: 10.1186/1471-2458-10-228
doi: 10.1186/1471-2458-10-228
Ameye L, Antoine C, Paesmans M, de Azambuja E, Rozenberg S. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas 2014;79:287–291. doi: 10.1016/j.maturitas.2014.07.002
doi: 10.1016/j.maturitas.2014.07.002